Recent Advances in Epigenetic Anticancer Therapeutics and Future Perspectives

Overview

Journal Front Genet

Date 2023 Jan 23

PMID 36685834

Authors

Liwen Ren

Yihui Yang

Wan Li

Hong Yang

Yizhi Zhang

Binbin Ge

Sen Zhang

Guanhua Du

Jinhua Wang

Affiliations

Soon will be listed here.

Abstract

Tumor development is frequently accompanied by abnormal expression of multiple genomic genes, which can be broadly viewed as decreased expression of tumor suppressor genes and upregulated expression of oncogenes. In this process, epigenetic regulation plays an essential role in the regulation of gene expression without alteration of DNA or RNA sequence, including DNA methylation, RNA methylation, histone modifications and non-coding RNAs. Therefore, drugs developed for the above epigenetic modulation have entered clinical use or preclinical and clinical research stages, contributing to the development of antitumor drugs greatly. Despite the efficacy of epigenetic drugs in hematologic caners, their therapeutic effects in solid tumors have been less favorable. A growing body of research suggests that epigenetic drugs can be applied in combination with other therapies to increase efficacy and overcome tumor resistance. In this review, the progress of epigenetics in tumor progression and oncology drug development is systematically summarized, as well as its synergy with other oncology therapies. The future directions of epigenetic drug development are described in detail.

Citing Articles

Epigenetic drugs in cancer therapy.

Suraweera A, OByrne K, Richard D Cancer Metastasis Rev. 2025; 44(1):37.

PMID: 40011240 PMC: 11865116. DOI: 10.1007/s10555-025-10253-7.

Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies.

Tahghighi A, Seyedhashemi E, Mohammadi J, Moradi A, Esmaeili A, Pornour M Clin Epigenetics. 2025; 17(1):34.

PMID: 39987205 PMC: 11847397. DOI: 10.1186/s13148-025-01844-w.

Integrating alternative therapies in overcoming chemotherapy resistance in tumors.

Alqarni S, Khan N Mol Biol Rep. 2025; 52(1):239.

PMID: 39961936 DOI: 10.1007/s11033-025-10361-1.

A View of Myeloid Transformation through the Hallmarks of Cancer.

Fernandez-Maestre I, Cai S, Levine R Blood Cancer Discov. 2024; 5(6):377-387.

PMID: 39422551 PMC: 11528188. DOI: 10.1158/2643-3230.BCD-24-0009.

Acyl-CoA Synthetase Medium-Chain Family Member 5-Mediated Fatty Acid Metabolism Dysregulation Promotes the Progression of Hepatocellular Carcinoma.

Yang L, Pham K, Xi Y, Jiang S, Robertson K, Liu C Am J Pathol. 2024; 194(10):1951-1966.

PMID: 39069168 PMC: 11423759. DOI: 10.1016/j.ajpath.2024.07.002.

References

Hughes A, Kelley J, Klose R . Understanding the interplay between CpG island-associated gene promoters and H3K4 methylation. Biochim Biophys Acta Gene Regul Mech. 2020; 1863(8):194567. PMC: 7294231. DOI: 10.1016/j.bbagrm.2020.194567. View

Pan K, Hu B, Wang L, Yuan J, Xu W . STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells. J Mol Neurosci. 2022; 72(9):2030-2044. DOI: 10.1007/s12031-022-02051-5. View

Ribrag V, Kim W, Bouabdallah R, Lim S, Coiffier B, Illes A . Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017; 102(5):903-909. PMC: 5477609. DOI: 10.3324/haematol.2016.154377. View

Li Q, Qu B, Shen H, Deng H, Sun L . Histone Demethylase GASC1 Inhibitor Targeted GASC1 Gene to Inhibit the Malignant Transformation of Esophageal Cancer through the NOTCH-MAPK Signaling Pathway. Ann Clin Lab Sci. 2022; 52(2):240-248. View

Peterson L, Kurland B, Yan F, Jiresova A, Gadi V, Specht J . F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer. J Nucl Med. 2020; 62(2):184-190. PMC: 9364869. DOI: 10.2967/jnumed.120.244459. View

Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G . Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Rep. 2018; 25(4):1066-1080.e8. DOI: 10.1016/j.celrep.2018.09.082. View

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

Liu Q, Wang M . Histone lysine methyltransferases as anti-cancer targets for drug discovery. Acta Pharmacol Sin. 2016; 37(10):1273-1280. PMC: 5057236. DOI: 10.1038/aps.2016.64. View

Byun M, Lee D, Jang Y, Lee H, Choi J, Lee S . Repurposing natural products as novel HDAC inhibitors by comparative analysis of gene expression profiles. Phytomedicine. 2019; 59:152900. DOI: 10.1016/j.phymed.2019.152900. View

10.

Rodriguez C, Wu Q, Voutsinas J, Fromm J, Jiang X, Pillarisetty V . A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clin Cancer Res. 2019; 26(4):837-845. DOI: 10.1158/1078-0432.CCR-19-2214. View

11.

Flausino C, Daniel F, Modolo F . DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs. Crit Rev Oncol Hematol. 2021; 164:103399. DOI: 10.1016/j.critrevonc.2021.103399. View

12.

Yu J, Xie T, Wang Z, Wang X, Zeng S, Kang Y . DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs. Drug Discov Today. 2019; 24(12):2323-2331. DOI: 10.1016/j.drudis.2019.08.006. View

13.

Jiang Y, Xiang C, Zhong F, Zhang Y, Wang L, Zhao Y . Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics. 2021; 11(1):361-378. PMC: 7681085. DOI: 10.7150/thno.46360. View

14.

Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A . In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005; 15(1):39-48. DOI: 10.3727/096504005775082066. View

15.

Sun N, Zhang J, Zhang C, Zhao B, Jiao A . DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells. Oncol Lett. 2018; 16(5):5799-5806. PMC: 6176375. DOI: 10.3892/ol.2018.9390. View

16.

Bijian K, Kaldre D, Wang T, Su J, Bouttier M, Boucher A . Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. J Steroid Biochem Mol Biol. 2017; 177:135-139. DOI: 10.1016/j.jsbmb.2017.08.010. View

17.

Black J, Van Rechem C, Whetstine J . Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012; 48(4):491-507. PMC: 3861058. DOI: 10.1016/j.molcel.2012.11.006. View

18.

Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon V . Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009; 2:31. PMC: 2731787. DOI: 10.1186/1756-8722-2-31. View

19.

Richards D, Boehm K, Waterhouse D, Wagener D, Krishnamurthi S, Rosemurgy A . Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol. 2006; 17(7):1096-102. DOI: 10.1093/annonc/mdl081. View

20.

Gravina G, Festuccia C, Marampon F, Popov V, Pestell R, Zani B . Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010; 9:305. PMC: 3001713. DOI: 10.1186/1476-4598-9-305. View